Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01560624 · ClinicalTrials.gov registry record · Phase 3
Phase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral Monotherapy
A Phase 3 study, sponsored by United Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 690
- Enrollment target
NCT01560624 is a Phase 3 study that has completed, run by United Therapeutics. The registered enrollment target is 690 participants.
The verdict
NCT01560624, a Phase 3 study, has completed, sponsored by United Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 690 participants
- Enrollment target
Study Summary
This is an international, multicenter, randomized, double-blind, placebo-controlled, event driven study in subjects with pulmonary arterial hypertension.
Interventions
- DRUG Placebo
- DRUG Treprostinil Diolamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 690 participants |
| Start Date | 2012-06-26 |
| Est. Completion | 2018-06-24 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01560624
The ClinicalTrials.gov registry entry for NCT01560624 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 690 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is United Therapeutics, which has 63 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01560624 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01560624 about?
NCT01560624 is a clinical study titled "Phase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral Monotherapy". This is an international, multicenter, randomized, double-blind, placebo-controlled, event driven study in subjects with pulmonary arterial hypertension.
What is the current status of trial NCT01560624?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 690 participants. The study started on 2012-06-26. Estimated completion is 2018-06-24.
What interventions are being tested in trial NCT01560624?
The interventions under investigation include: Placebo (DRUG), Treprostinil Diolamine (DRUG).
Who is sponsoring clinical trial NCT01560624?
This trial is sponsored by United Therapeutics, which has 63 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.